You have 9 free searches left this month | for more free features.

DLBCL

Showing 1 - 25 of 915

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With

Completed
  • DLBCL
  • Old Age; Debility
    • Homburg, Saarland, Germany
      Saarland University Medical Center
    Nov 20, 2023

    DLBCL - Diffuse Large B Cell Lymphoma, Lymphoma Trial in Shanghai (Other)

    Not yet recruiting
    • DLBCL - Diffuse Large B Cell Lymphoma
    • Lymphoma
    • Other
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Sep 6, 2023

    Diffuse Large B Cell Lymphoma (DLBCL) Trial in Toronto (glofitamab)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma (DLBCL)
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Sep 18, 2023

    DLBCL Trial in Suzhou (Chidamide, Azacitidine, obinutuzumab)

    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • Suzhou, Jiangsu, China
      the First Affiliated Hospital of Soochow University
    Apr 10, 2023

    Diffuse Large B-cell Lymphoma (DLBCL) Trial in Lanzhou (Zanubrutinib)

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • Lanzhou, Gansu, China
      The First Hospital of Lanzhou University
    Oct 23, 2022

    Orelabrutinib in Combination With Standard Treatment Regimen for

    Not yet recruiting
    • Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type
    • Nanjing, Jiangsu, China
      Hematological Department, People's Hospital of Jiangsu Province
    Aug 23, 2023

    Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:

    Completed
    • Diffuse Large B-cell Lymphoma
      • East Hanover, New Jersey
        Novartis
      Jun 16, 2023

      DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

      Not yet recruiting
      • Diffuse Large B-Cell Lymphoma
      • Mitoxantrone Hydrochloride Liposome Injection
      • Jinan, Shandong, China
        Affiliated Cancer Hospital of Shandong First Medical University
      May 16, 2023

      Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)

      Recruiting
      • Diffuse Large B Cell Lymphoma,DLBCL
      • PM 8.4 mg/m2
      • PM 11.2 mg/m2
      • Chengdu, Sichuan, China
        West China Hospital Sichuan University
      Jan 15, 2023

      DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)

      Recruiting
      • DLBCL
      • +3 more
      • Minneapolis, Minnesota
        University of Minnesota, Masonic Cancer Center
      Jul 1, 2022

      Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)

      Recruiting
      • Large B-cell Lymphoma
      • DLBCL
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      Oct 3, 2022

      Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
      • Shenyang, Liaoning, China
        Xing Xiaojing
      Jun 1, 2023

      Diffuse Large B Cell Lymphoma Trial in Tampa (Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy)

      Recruiting
      • Diffuse Large B Cell Lymphoma
      • Itacitinib
      • Chimeric antigen receptor (CAR) T-cell therapy
      • Tampa, Florida
        Moffitt Cancer Center
      Mar 6, 2023

      Lymphomas Non-Hodgkin's B-Cell Trial in Ballarat, Box Hill, Heidelberg (Avelumab)

      Active, not recruiting
      • Lymphomas Non-Hodgkin's B-Cell
      • Ballarat, Victoria, Australia
      • +2 more
      Jan 30, 2023

      Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)

      Recruiting
      • Diffuse Large B-cell Lymphoma
      • Metabolically Armed CD19 CAR-T cells
      • Hangzhou, Zhejiang, China
        The first affiliated hospital of medical college of zhejiang uni
      Nov 1, 2023

      Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma

      Completed
      • Diffuse Large B-cell Lymphoma (DLBCL)
      • CAR-T
      • Allo-HSCT cohort
      • East Hanover, New Jersey
        Novartis Investigative Site
      Jun 29, 2022

      DLBCL Trial in Japan (MT-2111)

      Recruiting
      • Diffuse Large B-Cell Lymphoma
      • Nagoya-shi, Aichi, Japan
      • +3 more
      Jan 12, 2023

      DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))

      Recruiting
      • DLBCL - Diffuse Large B Cell Lymphoma
      • Follicular Lymphoma
      • Lenalidomide combined with G-CHOP (LO CHOP)
      • Xiamen, Fujian, China
        Bing Xu
      Nov 28, 2023

      Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)

      Recruiting
      • Diffuse Large B Cell Lymphoma
      • +2 more
      • Madison, Wisconsin
        University of Wisconsin Carbone Cancer Center
      Dec 12, 2022

      Including miRNA-based Tumor Signatures in Diffuse Large B Cell

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
      • Relapsed Non-Hodgkin Lymphoma
      • no intervention (observational study)
      • Napoli, Italy
      • +2 more
      Feb 17, 2023

      Diffuse Large B-cell Lymphoma Trial in Hefei (Metabolically Armed CD19 CAR-T cells)

      Recruiting
      • Diffuse Large B-cell Lymphoma
      • Metabolically Armed CD19 CAR-T cells
      • Hefei, Anhui, China
        Anhui Provincial Hospital
      Feb 9, 2023

      DLBCL Trial in Suzhou (Orelabrutinib, Rituximab, CHOP-like Regimen)

      Recruiting
      • Diffuse Large B-Cell Lymphoma
      • Suzhou, Jiangsu, China
        the First Affiliated Hospital of Soochow University
      Aug 10, 2022

      Diffuse Large B Cell Lymphoma (DLBCL) Trial in Shanghai (Orelabrutinib + R-CHOP, Placebo + R-CHOP)

      Recruiting
      • Diffuse Large B Cell Lymphoma (DLBCL)
      • Orelabrutinib + R-CHOP
      • Placebo + R-CHOP
      • Shanghai, Shanghai, China
        Shanghai Ruijing Hospital
      Nov 28, 2022

      DLBCL Trial in Hangzhou (Tafasitamab and Lenalidomide)

      Recruiting
      • DLBCL
      • Tafasitamab and Lenalidomide
      • Hangzhou, Zhejiang, China
        The First Afflicated Hospital, College of Medicine, Zhejiang Uni
      Sep 21, 2022

      DLBCL Trial in Qingdao (Selinexor combined with Prednisone, Etoposide, and Lenalidomide)

      Not yet recruiting
      • DLBCL
      • Selinexor combined with Prednisone, Etoposide, and Lenalidomide
      • Qingdao, Shandong, China
        the affiliated hospital of Qingdao University
      Aug 18, 2022